We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets closed

ContraFect Corporation (CFRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.65-0.17 (-6.03%)
At close: 4:00PM EDT
Full screen
Previous Close2.82
Open2.81
Bid2.65 x 1000
Ask3.75 x 900
Day's Range2.60 - 2.92
52 Week Range0.80 - 2.93
Volume301,317
Avg. Volume126,782
Market Cap195.195M
Beta0.59
PE Ratio (TTM)N/A
EPS (TTM)-0.44
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.56
Trade prices are not sourced from all markets
  • Zacks Small Cap Research26 days ago

    CFRX: Developing Gram-Negative Lysin Targeting P. aeruginosa

    In June 2018, ContraFect Corp. (CFRX) had multiple presentations at the American Society for Microbiology (ASM) Microbe 2018 on the company’s lead drug candidate CF-301 and the Gram-negative lysin discovery program. This study was undertaken as part of ContraFect’s Gram-negative lysin discovery program. Gram-negative (GN) bacteria are responsible for a number of different bacterial infections and the emergence of antibiotic resistant strains is leading to a potential public health crisis.

  • GlobeNewswirelast month

    ContraFect to Present at JMP Securities Life Sciences Conference

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, M.D., the Company's Executive Vice President of Research and Development and Chief Medical Officer, will participate in an analyst-led fireside chat at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018 at 1:30 PM ET in New York, NY.  The chat will feature a one-on-one conversation followed by an interactive question and answer session. ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings.

  • PR Newswirelast month

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

    88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...

  • Business Wirelast month

    Glancy Prongay & Murray LLP Continues Investigation on Behalf of ContraFect Corporation Investors (CFRX)

    Glancy Prongay & Murray LLP continues its investigation on behalf of ContraFect Corporation investors concerning the Company and its directors’ and officers’ possible violations of state laws.

  • GlobeNewswirelast month

    ContraFect to Present New Data on CF-301 (exebacase) and Lysins Targeting Gram-Negative Pathogens at ASM Microbe 2018

    YONKERS, N.Y., May 30, 2018-- ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant ...

  • Zacks Small Cap Research2 months ago

    CFRX: Multiple Presentations on CF-301 at ECCMID

    The catheter was removed as part of the patient’s care and segmented into different treatment groups: CF-301, daptomycin, or CF-301 + daptomycin with each compound used at concentrations of 1 μg/mL (a clinically relevant dose), 10 μg/mL, or 100 μg/mL. This study involved the use of an aortic valve infective endocarditis (IE) model in rabbits using methicillin-resistant Staphylococcus aureus (MRSA) strain MW2.

  • Associated Press2 months ago

    ContraFect: 1Q Earnings Snapshot

    On a per-share basis, the Yonkers, New York-based company said it had a loss of 26 cents. Losses, adjusted for non-recurring costs, were 9 cents per share. The results matched Wall Street expectations. ...

  • GlobeNewswire2 months ago

    ContraFect Announces First Quarter 2018 Financial Results

    YONKERS, N.Y., May 10, 2018-- ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant ...

  • PR Newswire3 months ago

    Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...

  • Lysins plus antibiotics: A cure for human bacterial infections?
    Reuters Videoslast month

    Lysins plus antibiotics: A cure for human bacterial infections?

    Scientists in New York have found that a protein called lysin extracted from bacteriophage could lead to life-saving medicine to combat antibiotic-resistant infections. The drugs have reached the first human trials, after decades of research. Roselle Chen reports.